← Back to Home

Acadia releases additional analyses of investigational drug for Alzheimer’s psychosis after primary endpoint miss

The Phase 2 trial of remlifanserin showed signals of improvement across several symptom measures, but the additional analyses are not yet sufficient to establish efficacy. Acadia continues to advance Phase 3 studies to test whether the 60 mg dose can deliver reliable clinical benefits.

By SURL BioNews

The challenges faced by people with Alzheimer’s disease sometimes extend beyond gradual memory loss to include hallucinations and delusions. Remlifanserin, which is being developed to address these symptoms, has yielded further findings supporting continued research after missing the primary endpoint in a Phase 2 trial. On November 17, Acadia Pharmaceuticals presented additional analyses at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston: 60 mg daily outperformed placebo on several measures, but these results do not change the conclusion that the primary endpoint was not met.

Remlifanserin is a highly selective serotonin 5-HT2A receptor inverse agonist being developed to reduce psychotic symptoms. The Phase 2 RADIANT study randomized 363 participants to 60 mg daily, 30 mg daily, or placebo for a six-week double-blind comparison; eligibility criteria included clinically diagnosed and biomarker-supported Alzheimer’s disease. The efficacy analysis used a prespecified modified full analysis set comprising 326 participants.

The conference data added detail to the initial results released in September. The study primarily assessed hallucinations and delusions using the SAPS-H+D scale. At week six, scores fell by 12.6 points in the 60 mg group and 10.4 points in the placebo group, a between-group difference of 2.2 points; the p-value was 0.0603, which did not reach statistical significance. The placebo group also showed substantial improvement, highlighting the difficulty of determining the drug’s additional benefit. The 30 mg group showed only limited efficacy.

In the additional analyses, the Clinical Global Impression of Improvement assessment (CGI-I-ADP) favored the 60 mg group at weeks two, four, and six; at week six, 44.0% were rated much or very much improved, compared with 31.8% in the placebo group. The psychosis score on another neuropsychiatric symptom scale also showed a favorable difference at week six. These comparisons, along with the previously reported key secondary endpoint, were all nominally statistically significant. Interpretation must account for the limitations of multiple comparisons and the failure of the primary endpoint; these findings cannot be taken directly as evidence confirming efficacy.

The research team also found that the estimated treatment effect tended to increase as higher baseline symptom severity thresholds were used in the analysis. This offers a direction for further research to test: whether treatment differences are more readily apparent in people with more severe symptoms. However, the threshold analysis itself does not establish that these patients benefit more, nor is it sufficient to determine which patients should receive the drug in clinical practice.

Regarding safety, treatment-emergent adverse events occurred in 36.8% of the 60 mg group and 41.7% of the placebo group; serious adverse events occurred in 1.6% and 2.6%, respectively. The company said the study observed no worsening in cognitive or motor symptom measures relative to placebo, and no deaths occurred in either drug group. These findings come from six weeks of observation. For patients who need long-term treatment, longer follow-up and larger datasets are still needed to assess risks.

Acadia continues to advance the RADIANT Phase 3 development program; in September, the company said it would continue enrollment in the two ongoing Phase 3 trials and amend the protocols to remove the 30 mg group. The newly released data come from company-funded research and a conference presentation, providing a basis for dose selection and subsequent validation. The key question now is whether the Phase 3 studies can reproduce benefits on their prespecified primary endpoints and clarify whether the symptom improvements are sufficient to make a practical difference for patients.

References

  1. Acadia Pharmaceuticals
  2. Acadia Pharmaceuticals
  3. Acadia Pharmaceuticals
  4. Acadia Pharmaceuticals